Work

Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8018

Authors: Suresh S. Ramalingam, Pasi A. Janne, Tony Mok, Kenneth O'Byrne, Michael J. Boyer, Hui Zhang, Jane Q. Liang, Jim P. Doherty, Ian Taylor, Cecile A. Mather, Joseph P. O'Connell, Luis Paz-Ares

Institutions: Emory University, Winship Cancer Institute, Dana-Farber Cancer Institute, Prince of Wales Hospital, Queensland University of Technology, Royal Prince Alfred Hospital, Chris O’Brien Lifehouse, Pfizer (China), Pfizer (United States), Hospital Universitario Virgen del Rocío

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597424080

Cites:

Cited by: 16

Related to: 10